Silence Therapeutics (SLN) Interest Coverage Ratio (2024 - 2025)
Silence Therapeutics (SLN) posted Interest Coverage Ratio of 0.15 for Q4 2025, down 118.79% sequentially from 0.07 in Q4 2024, and down 118.79% YoY from 0.82 in Q4 2024.
Silence Therapeutics (SLN) Interest Coverage Ratio (2024 - 2025) Analysis & Trends
Silence Therapeutics has reported Interest Coverage Ratio for 2 years, with the latest figure at 0.15 in Q4 2025.
- Quarterly Interest Coverage Ratio fell 118.79% year-over-year to 0.15 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.13 (down 9.91% YoY) and the FY2025 annual result came in at 1.13, down 9.91% from the prior year.
- Interest Coverage Ratio retreated to 0.15 in Q4 2025 per SLN's latest filing, from 0.07 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.07 in Q4 2024 and troughed at 0.15 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.15 |
| Dec 31, 2024 | -0.07 |